Kinetics of c-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times

Biomarkers

Volumn 16, Issue 6, 2011, Pages 530-535

  Takata, Saori ^a   Wada, Hiroo ^a   Tamura, Masaki ^a   Koide, Takashi ^a   Higaki, Manabu ^a   Mikura, Shin Ichiro ^a   Yasutake, Tetsuo ^a   Hirao, Susumu ^a   Nakamura, Masuo ^a   Honda, Koujiro ^a   Nagatomo, Tomoko ^a   Tanaka, Yasutaka ^a   Sohara, Erei ^a   Watanabe, Masato ^a   Yokoyama, Takuma ^a   Saraya, Takeshi ^a   Kurai, Daisuke ^a   Ishii, Haruyuki ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

biologic half life time; C reactive protein (CRP); Community acquired pneumonia (CAP); kinetics; serum amyloid A (SAA)

Indexed keywords

C REACTIVE PROTEIN; SERUM AMYLOID A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; FEMALE; HALF LIFE TIME; HUMAN; MALE; PROTEIN DETERMINATION;

EID: 80051990661     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.607189     Document Type: Article

References (17)

1. Coelho L, Póvoa Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. (2007). Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 11:R92.
2. The committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. (2006). Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 11 Suppl 3: S79-S133
3. The committee for the Japanese Respiratory Society guidelines in management of respiratory infections. (2006). The JRS guidelines for the management of hospital-acquired pneumonia in adults. Nihon Kokyuki Gakkai Zasshi 45 Suppl: 2-85 [Article in Japanese]
4. Hoffman JS, Benditt EP. (1983). Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest 71:926-934. (Pubitemid 13163265)
5. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin AL. (2003). A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 44:1489-1498. (Pubitemid 37279593)
6. Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, Karlsson AS, Silvestrini R, Smallwood D, Vlahos R, Irving LB, Anderson GP. (2007). Serum amyloid A is a biomarker of acute exacerbations of COPD. Am J Respir Crit Care Med 177:269-278.
7. Jensen LE, Whitehead AS. (1998). Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 334 (Pt 3):489-503. (Pubitemid 28457193)
8. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE; National Heart, Lung, and Blood Institute. (2004). Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute- Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109:726-732. (Pubitemid 38222891)
9. Kindy MS, King AR, Yu J, Gerardot C, Whitley J, de Beer FC. (1998). Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis. Biochem J 332 (Pt 3): 721-728. (Pubitemid 28306698)
10. Kluve-Beckerman B, Yamada T, Hardwick J, Liepnieks JJ, Benson MD. (1997). Differential plasma clearance of murine acutephase serum amyloid A proteins SAA1 and SAA2. Biochem J 322 (Pt 2):663-669. (Pubitemid 27116598)
11. Kohno S, Seki M, Watanabe A; CAP Study Group. (2011). Evaluation of an assessment system for the JRS 2005: A-DROP for the management of CAP in adults. Intern Med 50:1183-1191.
12. Lannerg?d A, Larsson A, Kragsbjerg P, Friman G. (2003). Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest 63:267-272. (Pubitemid 37006434)
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. (2007). Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2:S27-S72. (Pubitemid 46290553)
14. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI. (1996). Community acquired pneumonia: Aetiology and usefulness of severity criteria on admission. Thorax 51:1010-1016. (Pubitemid 26360177)
15. Tape C, Kisilevsky R. (1990). Apolipoprotein A-I and apolipoprotein SAA half-lives during acute inflammation and amyloidogenesis. Biochim Biophys Acta 1043:295-300. (Pubitemid 20103665)
16. Uhlar CM, Whitehead AS. (1999). Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523. (Pubitemid 29488982)
17. Wada A, Yamada T, Itoh Y, Itoh K. (1998). Sensitive enzyme-linked immunosorbent assay for human serum amyloid A (SAA) and application to clearance study. Rinsho Byori 46:1252-1257.